Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $756.00

Thermo Fisher Scientific (NYSE:TMO) had its price objective raised by Robert W. Baird from $723.00 to $756.00 in a research report sent to investors on Thursday morning, Marketbeat.com reports. They currently have an outperform rating on the medical research company’s stock.

Several other research firms also recently issued reports on TMO. Barclays boosted their price objective on Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Citigroup downgraded shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an “overweight” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $681.00.

Thermo Fisher Scientific Stock Down 0.4%

Shares of Thermo Fisher Scientific stock opened at $673.97 on Thursday. The stock’s fifty day moving average is $645.72 and its 200-day moving average is $554.80. The firm has a market capitalization of $249.20 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 2.80 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $705.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the prior year, the business posted $5.79 earnings per share. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific will post 25.23 earnings per share for the current year.

Insider Activity

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Institutional investors have recently made changes to their positions in the stock. Strengthening Families & Communities LLC raised its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock valued at $3,187,000 after acquiring an additional 21 shares during the last quarter. Bell Bank boosted its position in shares of Thermo Fisher Scientific by 10.8% in the 3rd quarter. Bell Bank now owns 624 shares of the medical research company’s stock worth $421,000 after purchasing an additional 61 shares during the last quarter. 55 North Private Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 40.9% in the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company’s stock worth $612,000 after purchasing an additional 263 shares during the last quarter. Jeppson Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth $213,000. Finally, James Hambro & Partners LLP grew its stake in shares of Thermo Fisher Scientific by 0.8% during the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company’s stock worth $156,260,000 after purchasing an additional 1,919 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.